Michael Megna
Comptroller/Controller/Auditor chez KINIKSA PHARMACEUTICALS, LTD.
Fortune : 420 801 $ au 31/03/2024
Profil
Michael R.
Megna is currently the Chief Accounting Officer & Vice President-Finance at Kiniksa Pharmaceuticals Ltd.
He previously worked as the Chief Accounting Officer & Corporate Controller at BioSphere Medical, Inc. from 2004 to 2010.
He also held the position of Senior Vice President-Finance & Accounting at LFB USA, Inc. Mr. Megna completed his undergraduate degree at Siena College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/04/2024 | 21 328 ( 0,05% ) | 420 801 $ | 31/03/2024 |
Postes actifs de Michael Megna
| Sociétés | Poste | Début |
|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Comptroller/Controller/Auditor | 04/02/2020 |
Anciens postes connus de Michael Megna
| Sociétés | Poste | Fin |
|---|---|---|
BioSphere Medical, Inc.
 BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | Comptroller/Controller/Auditor | 01/11/2010 |
LFB USA, Inc.
 LFB USA, Inc. Pharmaceuticals: MajorHealth Technology LFB USA, Inc. is a pharmaceutical company based in Framingham, MA. The private company develops and provides pharmaceutical bioproducts through innovative technologies for patients with serious diseases. LFB USA is committed to improving people's lives by overcoming barriers through purposeful science. The company offers a robust set of services that powers its own pipeline to its partners. LFB USA's rpro technology is revolutionizing recombinant protein production for a new generation of therapeutics. The company is ultimately controlled by the Government of France. Jose Antonio Moreno Toscano has been the CEO of the company since 2018. | Comptroller/Controller/Auditor | - |
Formation de Michael Megna
| Siena College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
BioSphere Medical, Inc.
BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | Health Technology |
LFB USA, Inc.
LFB USA, Inc. Pharmaceuticals: MajorHealth Technology LFB USA, Inc. is a pharmaceutical company based in Framingham, MA. The private company develops and provides pharmaceutical bioproducts through innovative technologies for patients with serious diseases. LFB USA is committed to improving people's lives by overcoming barriers through purposeful science. The company offers a robust set of services that powers its own pipeline to its partners. LFB USA's rpro technology is revolutionizing recombinant protein production for a new generation of therapeutics. The company is ultimately controlled by the Government of France. Jose Antonio Moreno Toscano has been the CEO of the company since 2018. | Health Technology |
